H.C. Wainwright analyst Raghuram Selvaraju lowered the firm’s price target on Axsome Therapeutics to $190 from $200 and keeps a Buy rating on the shares. The analyst cites dilution from the latest equity financing for the target drop.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on AXSM:
- Short Report: Bearishness on BioXcel at record high amid trial conduct review
- William Blair biotech analyst to hold an analyst/industry conference call
- Axsome Therapeutics to Report Second Quarter 2023 Financial Results on August 7
- Axsome Therapeutics Initiates FOCUS Phase 3 Trial of Solriamfetol for the Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in Adults
- Axsome Therapeutics initiates FOCUS Phase 3 trial of solriamfetol in ADHD